Table 7. Clinicopathological features of 48 relapsed patients vs. 75 relapse-free patients.
Items | Number of patients | ||
---|---|---|---|
48 cases | 75 cases | P value | |
Menopause | |||
Yes | 23 (47.9%) | 33 (44%) | 0.713 |
No | 25 (52.1%) | 42 (56%) | |
Tumor size (cm) | |||
T1 (T≤2) | 12 (25%) | 29 (38.7%) | 0.004 |
T2 (2<T≤5) | 20 (41.7%) | 39 (52.0%) | |
T3 or lager (T>5) | 16 (33.3%) | 7 (9.3%) | |
Lymph node involvement | |||
N0 | 15 (31.3%) | 35 (46.7%) | 0.052 |
N1 | 10 (20.8%) | 23 (30.7%) | |
N2 | 23 (47.9%) | 17 (22.7%) | |
Tumor grade | |||
2 | 14 (29.2%) | 23 (30.7%) | 0.86 |
3 | 34 (70.8%) | 52 (69.3%) | |
Hormone receptor status | |||
Positive | 38 (79.2%) | 45 (60%) | 0.031 |
Negative | 10 (20.8%) | 30 (40%) | |
HER2 status | |||
Positive | 3 (6.3%) | 6 (8.0%) | 0.745 |
Negative | 45 (93.7%) | 69 (92.0%) | |
Ki67 index | |||
≥14% | 32 (66.7%) | 50 (66.7%) | 1 |
<14% | 16 (33.3%) | 25 (33.3%) | |
PIK3CA † | |||
Mutation | 11 (25%) | 4 (6.3%) | 0.006 |
Wild type | 33 (75%) | 59 (93.7%) | |
PIK3CA/AKT/KRAS* | |||
Mutation | 16 (34.0%) | 7 (9.6%) | 0.001 |
Wild type | 31 (66.0%) | 66 (90.4%) | |
PTEN loss¶ | |||
Yes | 16 (34.0%) | 29 (40.3%) | 0.493 |
No | 31 (66.0%) | 43 (59.7%) | |
PAM activation | |||
Yes | 30 (62.5%) | 35 (46.7%) | 0.086 |
No | 18 (37.5%) | 40 (53.3%) |
†, successful analysis of PIK3CA sequencing, 44 cases vs. 63 cases
*, Mutation in any gene of PIK3CA, AKT, KRAS, 47 cases vs. 73 cases
¶, successful analysis of PTEN IHC, 47 cases vs. 72 cases.